CDEK
← All drugs Report issue

dulaglutide

Trade name: trulicity

Peptideapproved

Approved

Sep 18, 2014

Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. — Wikipedia

Clinical trial activity

131 trials · 55 clinical orgs · 1 marketing orgs

Phase 1
36
Phase 2
68
Phase 3
46
Phase 4
19

Earliest trial started Apr 1, 2008 (NCT00630825)

Timeline

2000s

  1. Jan 1, 2008

    Eli Lilly — Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Eli Lilly — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2010

    Eli Lilly — Earliest Phase 3 Sponsor(trial)

  3. Sep 18, 2014

    Eli Lilly — Earliest FDA Approval

  4. Sep 18, 2014

    Eli Lilly — NDA Organization

  5. Sep 18, 2014

    Eli Lilly — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedSep 18, 2014

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • dulaglutide
  • dulaglutide
  • dulaglutide
  • dulaglutide
  • dulaglutide
  • dulaglutide
  • dulaglutide
  • dulaglutide
  • dulaglutide
  • dulaglutide
  • ly2189265
  • ly2189265
  • ly2189265
  • ly 2189265
  • ly-2189265
  • ly3002815
  • trulicity
  • trulicity
  • trulicity
  • trulicity

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07232719Phase 3Dec 31, 2025Eli Lilly
NCT07282041Phase 2/Phase 3 (Phase 3)Dec 2, 2025National University of Singapore
NCT07165028Phase 3Oct 15, 2025Eli Lilly
NCT07156539Phase 3Sep 30, 2025Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT06982846Phase 1Jun 6, 2025Eli Lilly
NCT06982859Phase 1Jun 2, 2025Eli Lilly
NCT07035093Phase 3May 29, 2025Eli Lilly
NCT07109700Phase 2Apr 30, 2025Hangzhou Zhongmei
NCT06859268Phase 3Apr 30, 2025Eli Lilly
NCT06851962Phase 4Apr 30, 2025University of Valencia
NCT06808802Phase 1Feb 28, 2025Eli Lilly
NCT06739122Phase 3Jan 31, 2025Eli Lilly
NCT06662383Phase 3Nov 1, 2024Eli Lilly
NCT06533527N/AJul 31, 2024The Cleveland Clinic
NCT06257966Phase 3Jul 17, 2024Beijing Dongfang Biotech Co., Ltd., Peking University
NCT06383390Phase 3Apr 30, 2024Eli Lilly
NCT06354660Phase 3Apr 10, 2024Eli Lilly
NCT06235086Phase 3Mar 31, 2024Shijiazhuang Pharma Group (CSPC)
NCT06324461Phase 4Mar 20, 2024The Research Grants Council, Hong Kong, The University of Hong Kong
NCT06313528Phase 1Mar 20, 2024Eli Lilly
Showing 20 of 131 trials
Page 1 / 7

Organizations

Research & Development (55)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Eli LillyFor profit858442008
University of BaselAcademic/Hospital4212016
Innovent Biologics (Suzhou) Co. Ltd.For profit3322020
Novo NordiskFor profit3322016
Peking UniversityAcademic/Hospital3032022
Emory UniversityAcademic/Hospital2212019
Jiangsu Hansoh Pharmaceutical Co., Ltd.For profit2222024
SanofiFor profit2212016
Shijiazhuang Pharma Group (CSPC)For profit2222022
University of BernAcademic/Hospital2212016
Al Ain UniversityAcademic/Hospital1012020
Beijing Dongfang Biotech Co., Ltd.For profit1112024
Berry ConsultantsFor profit1012008
Central South UniversityAcademic/Hospital1112021
Chinese University of Hong KongAcademic/Hospital1112022
Chonbuk National UniversityAcademic/Hospital1112020
Corporacion Parc TauliAcademic/Hospital1112020
Department of Veteran AffairsGovernment1012022
Fudan UniversityAcademic/Hospital1012023
Goldschmidt-Jacobson FoundationAcademic/Hospital1012021
55 organizations
Page 1 / 3

Marketing (2)

OrganizationOrg typeRelationshipDate
Eli LillyFor profitNDASep 18, 2014
Eli LillyFor profitMKTGSep 18, 2014